Abstract
Cholangiocarcinomas are comparatively rare gastrointestinal neoplasms, and, while full extirpation is the mainstay of treatment, most patients present with locally advanced disease. Owing in part to numerical rarity, the optimum role of radiotherapy for EHCC remains an area of debate. The specific aim of this series is to derive baseline survival for EHCC patients receiving adjuvant radiotherapy, evaluated against comparative treatment cohorts, using a robust population based dataset.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
